vs
Side-by-side financial comparison of Ingevity Corp (NGVT) and Prestige Consumer Healthcare Inc. (PBH). Click either name above to swap in a different company.
Prestige Consumer Healthcare Inc. is the larger business by last-quarter revenue ($283.4M vs $185.4M, roughly 1.5× Ingevity Corp). Prestige Consumer Healthcare Inc. runs the higher net margin — 16.5% vs -45.6%, a 62.1% gap on every dollar of revenue. On growth, Ingevity Corp posted the faster year-over-year revenue change (36.7% vs -2.4%). Prestige Consumer Healthcare Inc. produced more free cash flow last quarter ($75.3M vs $73.5M). Over the past eight quarters, Prestige Consumer Healthcare Inc.'s revenue compounded faster (1.2% CAGR vs -26.2%).
Ingevity Corp is a global specialty chemicals and advanced materials manufacturer. It produces high-performance carbon materials, pavement preservation solutions, and specialty chemicals, serving automotive emissions control, industrial purification, road infrastructure, and agricultural input markets across North America, Europe, and Asia Pacific.
Prestige Consumer Healthcare Inc. is an American company that markets and distributes over-the-counter healthcare and household cleaning products. It was formed by the merger of Medtech Products, Inc., Prestige Brands International, and the Spic and Span Company in 1996. The company is headquartered in Tarrytown, New York and operates a manufacturing facility in Lynchburg, Virginia.
NGVT vs PBH — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.4M | $283.4M |
| Net Profit | $-84.6M | $46.7M |
| Gross Margin | 41.2% | 55.5% |
| Operating Margin | -47.7% | 29.1% |
| Net Margin | -45.6% | 16.5% |
| Revenue YoY | 36.7% | -2.4% |
| Net Profit YoY | -609.6% | -23.5% |
| EPS (diluted) | $-2.33 | $0.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.4M | $283.4M | ||
| Q3 25 | $333.1M | $274.1M | ||
| Q2 25 | $365.1M | $249.5M | ||
| Q1 25 | $284.0M | $296.5M | ||
| Q4 24 | $135.6M | $290.3M | ||
| Q3 24 | $333.8M | $283.8M | ||
| Q2 24 | $390.6M | $267.1M | ||
| Q1 24 | $340.1M | $277.0M |
| Q4 25 | $-84.6M | $46.7M | ||
| Q3 25 | $43.5M | $42.2M | ||
| Q2 25 | $-146.5M | $47.5M | ||
| Q1 25 | $20.5M | $50.1M | ||
| Q4 24 | $16.6M | $61.0M | ||
| Q3 24 | $-107.2M | $54.4M | ||
| Q2 24 | $-283.7M | $49.1M | ||
| Q1 24 | $-56.0M | $49.5M |
| Q4 25 | 41.2% | 55.5% | ||
| Q3 25 | 40.2% | 55.3% | ||
| Q2 25 | 37.8% | 56.2% | ||
| Q1 25 | 39.9% | 57.3% | ||
| Q4 24 | 81.3% | 55.5% | ||
| Q3 24 | 39.4% | 55.5% | ||
| Q2 24 | 31.5% | 54.7% | ||
| Q1 24 | 29.3% | 54.8% |
| Q4 25 | -47.7% | 29.1% | ||
| Q3 25 | 18.7% | 29.1% | ||
| Q2 25 | -39.1% | 28.8% | ||
| Q1 25 | 9.4% | 29.8% | ||
| Q4 24 | — | 31.7% | ||
| Q3 24 | 33.0% | 29.7% | ||
| Q2 24 | 25.9% | 27.0% | ||
| Q1 24 | 22.6% | 29.7% |
| Q4 25 | -45.6% | 16.5% | ||
| Q3 25 | 13.1% | 15.4% | ||
| Q2 25 | -40.1% | 19.0% | ||
| Q1 25 | 7.2% | 16.9% | ||
| Q4 24 | 12.2% | 21.0% | ||
| Q3 24 | -32.1% | 19.2% | ||
| Q2 24 | -72.6% | 18.4% | ||
| Q1 24 | -16.5% | 17.9% |
| Q4 25 | $-2.33 | $0.97 | ||
| Q3 25 | $1.18 | $0.86 | ||
| Q2 25 | $-4.02 | $0.95 | ||
| Q1 25 | $0.56 | $1.00 | ||
| Q4 24 | $0.44 | $1.22 | ||
| Q3 24 | $-2.94 | $1.09 | ||
| Q2 24 | $-7.81 | $0.98 | ||
| Q1 24 | $-1.54 | $0.98 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $78.1M | $62.4M |
| Total DebtLower is stronger | $1.2B | $1.0B |
| Stockholders' EquityBook value | $29.7M | $1.8B |
| Total Assets | $1.7B | $3.5B |
| Debt / EquityLower = less leverage | 39.10× | 0.56× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $78.1M | $62.4M | ||
| Q3 25 | $83.4M | $119.1M | ||
| Q2 25 | $76.9M | $139.5M | ||
| Q1 25 | $71.5M | $97.9M | ||
| Q4 24 | $68.0M | $50.9M | ||
| Q3 24 | $135.5M | $51.5M | ||
| Q2 24 | $107.4M | $34.3M | ||
| Q1 24 | $88.5M | $46.5M |
| Q4 25 | $1.2B | $1.0B | ||
| Q3 25 | $1.2B | $993.1M | ||
| Q2 25 | $1.2B | $992.7M | ||
| Q1 25 | $1.3B | $992.4M | ||
| Q4 24 | $1.3B | $992.0M | ||
| Q3 24 | $1.4B | $1.1B | ||
| Q2 24 | $1.4B | $1.1B | ||
| Q1 24 | $1.4B | $1.1B |
| Q4 25 | $29.7M | $1.8B | ||
| Q3 25 | $138.1M | $1.8B | ||
| Q2 25 | $120.7M | $1.9B | ||
| Q1 25 | $234.6M | $1.8B | ||
| Q4 24 | $195.2M | $1.8B | ||
| Q3 24 | $214.5M | $1.7B | ||
| Q2 24 | $284.8M | $1.7B | ||
| Q1 24 | $568.2M | $1.7B |
| Q4 25 | $1.7B | $3.5B | ||
| Q3 25 | $1.8B | $3.4B | ||
| Q2 25 | $1.9B | $3.4B | ||
| Q1 25 | $2.1B | $3.4B | ||
| Q4 24 | $2.0B | $3.3B | ||
| Q3 24 | $2.2B | $3.3B | ||
| Q2 24 | $2.3B | $3.3B | ||
| Q1 24 | $2.6B | $3.3B |
| Q4 25 | 39.10× | 0.56× | ||
| Q3 25 | 8.39× | 0.54× | ||
| Q2 25 | 10.24× | 0.54× | ||
| Q1 25 | 5.68× | 0.54× | ||
| Q4 24 | 6.86× | 0.55× | ||
| Q3 24 | 6.52× | 0.61× | ||
| Q2 24 | 4.92× | 0.65× | ||
| Q1 24 | 2.48× | 0.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $97.1M | $78.3M |
| Free Cash FlowOCF − Capex | $73.5M | $75.3M |
| FCF MarginFCF / Revenue | 39.6% | 26.6% |
| Capex IntensityCapex / Revenue | 12.7% | 1.1% |
| Cash ConversionOCF / Net Profit | — | 1.68× |
| TTM Free Cash FlowTrailing 4 quarters | $273.5M | $267.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $97.1M | $78.3M | ||
| Q3 25 | $129.7M | $57.5M | ||
| Q2 25 | $79.0M | $79.0M | ||
| Q1 25 | $25.4M | $61.8M | ||
| Q4 24 | $64.5M | $65.1M | ||
| Q3 24 | $46.5M | $69.8M | ||
| Q2 24 | $29.7M | $54.8M | ||
| Q1 24 | $-12.1M | $66.9M |
| Q4 25 | $73.5M | $75.3M | ||
| Q3 25 | $117.8M | $55.4M | ||
| Q2 25 | $66.8M | $78.2M | ||
| Q1 25 | $15.4M | $58.4M | ||
| Q4 24 | $39.6M | $63.5M | ||
| Q3 24 | $28.5M | $67.8M | ||
| Q2 24 | $11.6M | $53.6M | ||
| Q1 24 | $-28.7M | $63.8M |
| Q4 25 | 39.6% | 26.6% | ||
| Q3 25 | 35.4% | 20.2% | ||
| Q2 25 | 18.3% | 31.3% | ||
| Q1 25 | 5.4% | 19.7% | ||
| Q4 24 | 29.2% | 21.9% | ||
| Q3 24 | 8.5% | 23.9% | ||
| Q2 24 | 3.0% | 20.1% | ||
| Q1 24 | -8.4% | 23.0% |
| Q4 25 | 12.7% | 1.1% | ||
| Q3 25 | 3.6% | 0.8% | ||
| Q2 25 | 3.3% | 0.3% | ||
| Q1 25 | 3.5% | 1.2% | ||
| Q4 24 | 18.4% | 0.5% | ||
| Q3 24 | 5.4% | 0.7% | ||
| Q2 24 | 4.6% | 0.4% | ||
| Q1 24 | 4.9% | 1.1% |
| Q4 25 | — | 1.68× | ||
| Q3 25 | 2.98× | 1.36× | ||
| Q2 25 | — | 1.66× | ||
| Q1 25 | 1.24× | 1.23× | ||
| Q4 24 | 3.89× | 1.07× | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | — | 1.12× | ||
| Q1 24 | — | 1.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NGVT
| Performance Materials | $151.2M | 82% |
| Advanced Polymer Technologies Segment | $36.5M | 20% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
